FDA approval of ide-cel by 3/31/21 was one of the three requirements for the $9/sh Celgene CVR to pay off, but this became moot when a distinct CAR-T, liso-cel was not approved by its 12/31/20 deadline (#msg-160628371). The FDA approved liso-cel for DLBCL with the brand name, Breyanzi on 2/5/21 (#msg-161552697).